Skip to main content
HR 1020 115th Congress House Health Business records Civil actions and liability Drug safety, medical device, and laboratory regulation Drug therapy Health technology, devices, supplies Long-term, rehabilitative, and terminal care Prescription drugs Retail and wholesale trades Trade restrictions

Compassionate Freedom of Choice Act of 2017

Introduced: February 13, 2017 Introduced by: Griffith, H. Morgan Republican · Virginia See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 17, 2017
Referred to the Subcommittee on Health.
Feb 13, 2017
Referred to the House Committee on Energy and Commerce.
Feb 13, 2017
Introduced in House
 Plain-English summary Congressional Research Service

Compassionate Freedom of Choice Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to declare that nothing in that Act or in the Public Health Service Act prevents or restricts, and the Food and Drug Administration (FDA) may not prevent or restrict, the manufacture, importation, distribution, or sale of drugs or medical devices that are intended for terminally ill patients, have been the subject of a clinical trial, and have not been approved by the FDA.

The FDA may not require the disclosure, collection, or reporting of certain information concerning such drugs or devices. The sponsor of a clinical trial may voluntarily disclose, collect, or report such information to the FDA.

Except in the case of gross negligence or willful misconduct, a person who manufactures, imports, distributes, prescribes, or administers such a drug or device is not liable under state or federal law for loss, damage, or injury from the development, testing, production, acquisition, use, safety, or effectiveness of the drug or device.

What's happening now February 17, 2017

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2